Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy

Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy

Bibliographic Details
Main Authors:	Vipawee S. Chat, Donovan G. Kearns, Shelley K. Uppal, Jashin J. Wu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-07-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2019.1687812

Similar Items

Use of systemic therapies for psoriasis in the COVID-19 era
by: Donovan G. Kearns, et al.
Published: (2022-02-01)

Clinical management of psoriasis patients during the COVID-19 pandemic
by: Vipawee S. Chat, et al.
Published: (2022-02-01)

Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis
by: Shelley K. Uppal, et al.
Published: (2022-02-01)

Review of treatments for generalized pustular psoriasis
by: Donovan G. Kearns, et al.
Published: (2021-07-01)

Review of IL-17 inhibitors for psoriasis
by: Mina Amin, et al.
Published: (2018-05-01)

How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis
by: Mina Amin, et al.
Published: (2019-05-01)

Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions
by: Kevin K. Wu, et al.
Published: (2020-05-01)

Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis
by: Logan W. Thomas, et al.
Published: (2019-02-01)

Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review
by: Alexandra Norden, et al.
Published: (2022-11-01)

ATYPICAL MYCOBACTERIAL INFECTION
by: Aleksander Popov, et al.
Published: (2024-01-01)

IL-17 and -23 Inhibitors for the Treatment of Psoriasis
by: Sonali Batta, et al.
Published: (2023-04-01)

Atypical mycobacterial infections following laparoscopic surgery
by: WAMP Samaranayake, et al.
Published: (2018-05-01)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
by: Yu-Huei Huang, et al.
Published: (2023-02-01)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
by: Nicolo Costantino Brembilla, et al.
Published: (2018-08-01)

The Role of IL-17 Cytokines in Psoriasis
by: Mosca M, et al.
Published: (2021-11-01)

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
by: Georgios Kokolakis, et al.
Published: (2022-12-01)

An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
by: Olguța Anca Orzan, et al.
Published: (2023-08-01)

Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis
by: Daniel Octavian Costache, et al.
Published: (2022-05-01)

Diagnosis of atypical mycobacterial and fungal coinfection
by: Víctor Mato Jimeno, et al.
Published: (2020-01-01)

Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors
by: Yuta Koike, et al.
Published: (2020-05-01)

IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
by: Qiang Dong, et al.
Published: (2022-11-01)

Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report
by: Jingyi Ju, et al.
Published: (2020-10-01)

The contribution of IL-17 to the development of autoimmunity in psoriasis
by: Masutaka Furue, et al.
Published: (2019-08-01)

Nail psoriasis: dynamics of the clinical course during anti-IL-17 therapy
by: O. V. Zhukova, et al.
Published: (2022-03-01)

Language proficiency and biologics access: a population study of psoriasis patients in the United States
by: Vipawee S. Chat, et al.
Published: (2022-04-01)

Noncervicofacial atypical mycobacterial lymphadenopathy in a child
by: Iman Seleit, et al.
Published: (2014-01-01)

Two episodes of cutaneous non-tuberculous mycobacterial infection in a patient with psoriasis
by: Wai Sze Agnes Chan, et al.
Published: (2015-06-01)

Atypical mycobacterial infection mimicking carbuncle in an elderly patient: A case report
by: Terlinda Barros, et al.
Published: (2015-08-01)

Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review
by: Erica B. Lee, et al.
Published: (2018-10-01)

Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
by: Paolo Dapavo, et al.
Published: (2022-05-01)

Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors
by: Khalaf Kridin, et al.
Published: (2022-05-01)

IL-17A-driven psoriasis is critically dependent on IL-36 signaling
by: Berenice Fischer, et al.
Published: (2023-12-01)

Pharmacokinetic interactions of psychotropic medications in patients with schizophrenia suffering from atypical mycobacterial infections
by: M. Betriu Sabaté, et al.
Published: (2021-04-01)

Atypical mycobacterial infection, a diagnostic and therapeutic challenge-Case report and review of literature
by: Nupur Pal, et al.
Published: (2019-01-01)

Correction to: Atypical bronchial carcinoid with postobstructive mycobacterial infection: case report and review of literature
by: Abdulrahman Hakami, et al.
Published: (2019-11-01)

Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
by: Hélène Bugaut, et al.
Published: (2021-02-01)

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
by: Esther von Stebut, et al.
Published: (2020-01-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
by: Maria Concetta Fargnoli
Published: (2019-09-01)

Differentiation of IL-26+ TH17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis
by: Anissa Fries, et al.
Published: (2023-06-01)